NASDAQ:IBRX ImmunityBio (IBRX) Stock Price, News & Analysis $2.37 -0.09 (-3.66%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.38 +0.01 (+0.42%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ImmunityBio Stock (NASDAQ:IBRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ImmunityBio alerts:Sign Up Key Stats Today's Range$2.34▼$2.4250-Day Range$2.37▼$3.4452-Week Range$1.83▼$7.48Volume7.04 million shsAverage Volume7.48 million shsMarket Capitalization$2.09 billionP/E RatioN/ADividend YieldN/APrice Target$12.25Consensus RatingBuy Company Overview ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California. Read More ImmunityBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreIBRX MarketRank™: ImmunityBio scored higher than 45% of companies evaluated by MarketBeat, and ranked 598th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingImmunityBio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunityBio has only been the subject of 3 research reports in the past 90 days.Read more about ImmunityBio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ImmunityBio are expected to grow in the coming year, from ($0.92) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunityBio is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunityBio is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ImmunityBio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.72% of the outstanding shares of ImmunityBio have been sold short.Short Interest Ratio / Days to CoverImmunityBio has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in ImmunityBio has recently increased by 0.03%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunityBio does not currently pay a dividend.Dividend GrowthImmunityBio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.72% of the outstanding shares of ImmunityBio have been sold short.Short Interest Ratio / Days to CoverImmunityBio has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in ImmunityBio has recently increased by 0.03%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.64 News SentimentImmunityBio has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ImmunityBio this week, compared to 4 articles on an average week.Search Interest20 people have searched for IBRX on MarketBeat in the last 30 days. This is an increase of 54% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImmunityBio insiders have not sold or bought any company stock.Percentage Held by Insiders76.79% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.58% of the stock of ImmunityBio is held by institutions.Read more about ImmunityBio's insider trading history. Receive IBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBRX Stock News HeadlinesImmunitybio (IBRX) Targets $80 Million Capital Raise for Business OperationsAugust 1 at 11:45 AM | finance.yahoo.comImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder CancerJuly 31 at 11:49 AM | finance.yahoo.comThis rock I’m holding could be worth trillionsA strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.August 2 at 2:00 AM | Porter & Company (Ad)ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder CancerJuly 31 at 11:49 AM | insidermonkey.comImmunityBio's (IBRX) Buy Rating Reiterated at D. Boral CapitalJuly 28, 2025 | americanbankingnews.comImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory UpdatesJuly 25, 2025 | businesswire.comImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple ...July 25, 2025 | gurufocus.comImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional InvestorsJuly 25, 2025 | businesswire.comSee More Headlines IBRX Stock Analysis - Frequently Asked Questions How have IBRX shares performed this year? ImmunityBio's stock was trading at $2.56 at the start of the year. Since then, IBRX shares have decreased by 7.4% and is now trading at $2.37. How were ImmunityBio's earnings last quarter? ImmunityBio, Inc. (NASDAQ:IBRX) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.03. The company earned $16.52 million during the quarter, compared to the consensus estimate of $17.50 million. Who are ImmunityBio's major shareholders? ImmunityBio's top institutional investors include Plancorp LLC (0.03%), Blair William & Co. IL (0.03%), DekaBank Deutsche Girozentrale (0.02%) and Wealth Effects LLC (0.01%). Insiders that own company stock include Michael D Blaszyk and John Owen Brennan. View institutional ownership trends. How do I buy shares of ImmunityBio? Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImmunityBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunityBio investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Home Depot (HD), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/12/2025Today8/02/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IBRX CIK1326110 Webimmunitybio.com Phone(858) 633-0300FaxN/AEmployees590Year FoundedN/APrice Target and Rating Average Price Target for ImmunityBio$12.25 High Price Target$30.00 Low Price Target$5.00 Potential Upside/Downside+416.9%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$413.56 million Net Margins-1,310.30% Pretax Margin-1,311.30% Return on EquityN/A Return on Assets-121.88% Debt Debt-to-Equity RatioN/A Current Ratio2.22 Quick Ratio2.05 Sales & Book Value Annual Sales$14.74 million Price / Sales141.91 Cash FlowN/A Price / Cash FlowN/A Book Value($0.57) per share Price / Book-4.16Miscellaneous Outstanding Shares882,620,000Free Float204,856,000Market Cap$2.09 billion OptionableOptionable Beta0.12 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:IBRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.